Stefano Ciardullo1, Cinzia Ballabeni2, Roberto Trevisan3, Gianluca Perseghin4. 1. Department of Medicine and Rehabilitation, Policlinico di Monza, Via Modigliani 10, Monza 20900, Italy; Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. 2. Nephrology and Dialysis, Policlinico di Monza, Italy. 3. Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy; Endocrinology and Diabetes Unit, ASST Papa Giovanni XXIII, Bergamo, Italy. 4. Department of Medicine and Rehabilitation, Policlinico di Monza, Via Modigliani 10, Monza 20900, Italy; Department of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. Electronic address: gianluca.perseghin@policlinicodimonza.it.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are frequent and progressive conditions that share traditional risk factors: obesity, type 2 diabetes and hypertension. AIMS: To evaluate whether an independent relationship exists between liver steatosis and fibrosis and different CKD phenotypes. METHODS: Cross sectional study based on data from the 2017-18 cycle of the National Health and Nutrition Examination Survey. Vibration controlled transient elastography (VCTE) was performed in a US representative sample allowing the simultaneous assessment of liver steatosis (CAP: controlled attenuation parameter) and fibrosis (LSM: liver stiffness measurement) and their relationships with CKD phenotypes (albuminuria and reduced estimated glomerular filtration rate, eGFR). RESULTS: 4746 adult participants had a complete VCTE exam. Prevalence of liver steatosis and significant fibrosis was 33.7% (95%CI: 30.9-36.6%) and 8.9% (95%CI: 7.5-10.5%), respectively. Logistic regression analysis showed that liver fibrosis, but not steatosis, was associated with albuminuria (OR 2.19, 95%CI: 1.49-3.20) and albuminuria or reduced eGFR (OR 2.18, 95%CI: 1.59-3.00) also when adjusted for age, sex, ethnicity, BMI, diabetes, blood pressure categories, glycated haemoglobin, use of renin-angiotensin-aldosterone system blockers and CAP. CONCLUSIONS: In the general US population liver fibrosis assessed using VCTE is associated with CKD, and in particular with the albuminuric phenotype, regardless of traditional risk factors.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are frequent and progressive conditions that share traditional risk factors: obesity, type 2 diabetes and hypertension. AIMS: To evaluate whether an independent relationship exists between liver steatosis and fibrosis and different CKD phenotypes. METHODS: Cross sectional study based on data from the 2017-18 cycle of the National Health and Nutrition Examination Survey. Vibration controlled transient elastography (VCTE) was performed in a US representative sample allowing the simultaneous assessment of liver steatosis (CAP: controlled attenuation parameter) and fibrosis (LSM: liver stiffness measurement) and their relationships with CKD phenotypes (albuminuria and reduced estimated glomerular filtration rate, eGFR). RESULTS: 4746 adult participants had a complete VCTE exam. Prevalence of liver steatosis and significant fibrosis was 33.7% (95%CI: 30.9-36.6%) and 8.9% (95%CI: 7.5-10.5%), respectively. Logistic regression analysis showed that liver fibrosis, but not steatosis, was associated with albuminuria (OR 2.19, 95%CI: 1.49-3.20) and albuminuria or reduced eGFR (OR 2.18, 95%CI: 1.59-3.00) also when adjusted for age, sex, ethnicity, BMI, diabetes, blood pressure categories, glycated haemoglobin, use of renin-angiotensin-aldosterone system blockers and CAP. CONCLUSIONS: In the general US population liver fibrosis assessed using VCTE is associated with CKD, and in particular with the albuminuric phenotype, regardless of traditional risk factors.
Authors: Celestin Missikpode; Holly Kramer; Scott J Cotler; Ramon Durazo-Arvizu; James P Lash; Eric Kallwitz; Jianwen Cai; Mark H Kuniholm; Sylvia E Rosas; Ana C Ricardo; Gregory A Talavera; Leopoldo Raij; Amber Pirzada; Martha L Daviglus Journal: BMC Nephrol Date: 2021-09-07 Impact factor: 2.388